Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infections
Monteil, V.; Devignot, S.; Klingstroem, J.; Thalin, C.; Kellner, M. J.; Christ, W.; Havervall, S.; Mereiter, S.; Knapp, S.; Montserrat, N.; Braunsfeld, B.; Kozieradzki, I.; Ali, O. H.; Hagelkrueys, A.; Stadlmann, J.; Oostenbrink, C.; Wirnsberger, G.; Penninger, J. M.; Mirazimi, A.
Show abstract
The recent emergence of the SARS-CoV-2 variant Omicron has caused considerable concern due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. Omicron is spreading rapidly around the globe and is suspected to account for most new COVID-19 cases in several countries, though the severity of Omicron-mediated disease is still under debate. It is therefore paramount to identify therapeutic strategies that inhibit the Omicron SARS-CoV-2 variant. Here we report using 3D structural modelling that Spike of Omicron can still associate with human ACE2. Sera collected after the second mRNA-vaccination did not exhibit a protective effect against Omicron while strongly neutralizing infection of VeroE6 cells with the reference Wuhan strain, confirming recent data by other groups on limited vaccine and convalescent sera neutralization efficacy against Omicron. Importantly, clinical grade recombinant human soluble ACE2, a drug candidate currently in clinical development, potently neutralized Omicron infection of VeroE6 cells with markedly enhanced potency when compared to reference SARS-CoV-2 isolates. These data show that SARS-CoV-2 variant Omicron can be readily inhibited by soluble ACE2, providing proof of principle of a viable and effective therapeutic approach against Omicron infections.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity 96%
- Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins 95%
- The Renin-Angiotensin System Modulates SARS-CoV-2 Entry via ACE2 Receptor 95%
Similar papers in this journal
- The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody 96%
- Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo 94%
- Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2 93%
Similar papers in this journal
- Nasal delivery of single-domain antibodies improve symptoms of SARS-CoV-2 infection in an animal model 95%
- A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses 95%
- Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals 95%
Similar papers in this journal
- Increased receptor affinity and reduced recognition by specific antibodies contribute to immune escape of SARS-CoV-2 variant Omicron 96%
- Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera 95%
- Prediction of SARS-CoV-2 Omicron Variant Immunogenicity, Immune Escape and Pathogenicity, through Analysis of Spike Protein-specific Core Unique Peptides 94%
Similar papers in this journal
- DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection 94%
- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. 94%
- SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.